Skip to main content

Table 4 Anticancer recombinant biopharmaceuticals approved until March 2015

From: Recombinant pharmaceuticals from microbial cells: a 2015 update

Drug name Cell factory Source Biological role Indications
Denileukin diftitox E. coli Fusion protein Diphtheria toxin fused to cytokine Cutaneous T-cell lymphoma
Endostatin E. coli Modified Collagen derivative Non-small cell lung cancer, metastatic colorectal cancer
Aldesleukin E. coli Modified Cytokine Metastatic renal cell carcinoma, metastatic melanoma, kidney cancer, angiosarcoma
Interleukin-2 E. coli Modified Cytokine Metastatic melanoma, metastatic renal cell carcinoma
Filgrastim E. coli Modified Cytokine Acute lymphocytic leukaemia, solid tumour
Interferon alpha-2a E. coli Modified Cytokine AIDS-related Kaposi’s sarcoma, follicular lymphoma, cutaneous T-cell lymphoma, melanoma, chronic myelocytic leukaemia, hairy cell leukaemia, renal cell carcinoma, kidney cancer
Interferon alpha-2b E. coli Modified Cytokine AIDS-related Kaposi’s sarcoma, pancreatic endocrine tumour, melanoma, non-Hodgkin lymphoma, leukaemia, hairy cell leukaemia, renal cell carcinoma, multiple myeloma, CML, follicular lymphoma, melanoma
Interferon alpha-1b E. coli Modified Cytokine Renal cell carcinoma, hairy cell leukaemia
Interferon gamma-1a E. coli Modified Cytokine Kidney cancer, sezary syndrome, mycosis fungoides
Tasonermin E. coli Natural Cytokine Soft tissue sarcoma
Molgramostim E. coli Modified Growth factor Myelodysplastic syndrome
Nartograstim E. coli Modified Growth factor Solid tumour
Palifermin E. coli Fraction Growth factor Metastatic renal cell carcinoma, metastatic melanoma
Sargramostim S. cerevisiae Modified Growth factor Acute myelocytic leukaemia
Ziv-aflibercept CHO cells Fusion protein Growth factor receptor fused to IgG1 Metastatic colorectal cancer
Thyrotropin alpha CHO cells Modified Hormone Thyroid cancer
Trastuzumab biosimilar CHO cells Modified Monoclonal antibody Breast cancer, gastric cancer, metastatic breast cancer
Rituximab biosimilar CHO cells Modified Monoclonal antibody Non-Hodgkin lymphoma, chronic lymphocytic leukaemia
Interferon alpha Human lymphoblastoid cells Modified Cytokine AIDS-related Kaposi’s sarcoma, multiple myeloma, non-Hodgkin lymphoma, CML, hairy cell leukaemia, renal cell carcinoma